Medtronic receives FDA warning
This article was originally published in Clinica
Medtronic has been issued with a warning from the FDA relating to quality issues at a Minneapolis, Minnesota plant that manufactures implantable drug infusion and neurostimulation products. In a letter dated July 3, the FDA told Medtronic that inspections of the plant revealed several violations of federal regulations, including: misbranding of devices: an inadequate complaint handling procedure; and failure to report malfunctions with its implantable SynchroMed pump, including catheter separation or fracture, and inflammatory masses and granulomas, all of which could lead to serious injury.
You may also be interested in...
GNC announces "significant" store and management staff furloughs and other cost-cutting moves "to protect the long-term prospects for the business." Vitamin Shoppe told customers that its stores remain open though it reduced business hours.
California-based biosensor patch company LifeSignals Group plans to file for an emergency use authorization from the US FDA for a new patch that can monitor vital signs to help individuals decide when to seek the help of a health care provider. See what LifeSignals’ CEO Surendar Magar said about it here.
Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.